United States securities and exchange commission logo





                              June 2, 2023

       Ryan Nebel
       Partner
       Olshan Frome Wolosky LLP
       1325 Avenue of the Americas
       New York, NY 10019

                                                        Re: Forte Biosciences,
Inc.
                                                            Preliminary Proxy
Statement filed by Camac Fund, LP et al.
                                                            Filed May 25, 2023
                                                            File No. 001-38052

       Dear Ryan Nebel:

              We have reviewed your filing and have the following comments. In
some of our
       comments, we may ask you to provide us with information so we may better
understand your
       disclosure.

               Please respond to these comments by providing the requested
information or advise us as
       soon as possible when you will respond. If you do not believe our
comments apply to your facts
       and circumstances, please tell us why in your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Preliminary Proxy Statement

       Background to the Solicitation, page 6

   1.                                                   Each statement or
assertion of opinion or belief must be clearly characterized as such, and
                                                        a reasonable factual
basis must exist for each such opinion or belief. Support for opinions
                                                        or beliefs should be
self-evident, disclosed in the proxy statement or provided to the staff
                                                        on a supplemental
basis. Provide support for the following:

                                                              your stated
belief that the company is "materially undervalued."
                                                              your statement
that the August 2022 sale of shares constituted an "unjustifiable
                                                            capital raise" and
that it was "highly dilutive."
                                                              your stated
concern that the company adopted a form of change in control and
                                                            severance agreement
"in response to Camac's investigation into possible
                                                            mismanagement at
the Company and widespread stockholder discontent and that the
                                                            agreements could
result in an unjustified transfer of wealth to insiders at the expense
 Ryan Nebel
Olshan Frome Wolosky LLP
June 2, 2023
Page 2
              of stockholders."
                your statement, on page 8, that the company's focus on the
development of FB-102 is
              "early-stage, highly speculative..."
2.       Refer to the entry for March 9, 2023. Please revise this entry to
clarify why company
         counsel indicated the company "seemed adamant" instead of presenting
the company's
         position directly. Clarify also the language that appears to indicate
that the company
         already believes Camac will prevail in the current contest.
Reasons for the Solicitation, page 8

3.       You must avoid issuing statements that directly or indirectly impugn
the character,
         integrity or personal reputation or make charges of illegal, improper
or immoral conduct
         without factual foundation. Please provide a factual foundation for
the disclosure
         included below. In this regard, note that the factual foundation for
such assertion must be
         reasonable. Refer to Rule 14a-9.

                your statement that the company's focus on the development of
FB-102 is "an effort
              by management to keep their jobs rather than create value for
stockholders."
                your statement that the company "seems content to disregard the
views of its
              stockholders..."
                your statement that "...it seems as though management believes
the Company is theirs
              to do as they please and they don't have to answer to
stockholders."
4.       Please provide us support for the disclosure in the first paragraph of
the third bullet point
         on page 8.
Proposal No. 1, Election of Directors, page 9

5.       Please disclose in an appropriate location in the proxy statement
whether the election of
         your nominees will result in the triggering or acceleration of any
company obligations.
        We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

         Please direct any questions to Dan Duchovny at (202) 551-3619.



FirstName LastNameRyan Nebel                                    Sincerely,
Comapany NameOlshan Frome Wolosky LLP
                                                                Division of
Corporation Finance
June 2, 2023 Page 2                                             Office of
Mergers & Acquisitions
FirstName LastName